- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00587067
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Study Overview
Detailed Description
This phase II study aims to evaluate regional chemotherapy in patients with unresectable primary hepatic malignancy. Specifically, eligible patients with hepatocellular carcinoma and peripheral cholangiocarcinoma, considered unresectable after review by the Hepatobiliary Surgery service, will undergo hepatic artery pump placement and continuous infusion of FUDR. The protocol includes radiological and biological correlative studies.
The primary objectives of the study are 1.) to assess the efficacy of continuous hepatic arterial infusion (HAI) of FUDR and dexamethasone (DEX) in patients with unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) and 2.)to assess patient tolerability of this therapy stratified by degree of underlying hepatic parenchymal disease, as determined on liver biopsy. Secondary objectives are 1.) to use dynamic MRI to evaluate changes in tumor perfusion during treatment and to correlate these findings with radiographic tumor response and 2.) to investigate molecular genetic changes associated with these tumors using comparative genomic hybridization and cDNA array from tumor and liver biopsy specimens obtained at the time of operation. All patients enrolled in the study will begin HAI FUDR at 0.16 mg/kg/day. An initial cohort of 12 patients will be enrolled and treated. Dose limiting toxicity (DLT) related to FUDR is defined by changes in liver function blood tests that are unrelated to disease progression or mechanical biliary obstruction. Modifications in the FUDR dose may be required. A patient will be considered intolerant of therapy if treatment must be stopped due to DLT at least once during the first 3 months. Treatment will continue as long as there is at least stable disease and acceptable toxicity.
If, in the initial cohort, 4 or more patients (> 30%) are intolerant of therapy or if there are not at least 2 responders, then the study will be terminated. Otherwise, accrual will continue to a maximum of 35 patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a liver mass that is radiographically consistent with HCC and a serum alpha fetoprotein (AFP) > 500 ng/dl do not require biopsy confirmation of the diagnosis.
- Patients with HCC or ICC undergoing exploration for a possible curative resection but found to have unresectable disease confined to the liver will be eligible, provided that no intraoperative findings would exclude them and prior informed consent has been obtained (see below).
- There must be <70% liver involvement by cancer, and the disease must be considered unresectable.
- Patients who have failed ablative therapy will be eligible.
- Patients must have a KPS > 60% and be considered candidates for general anesthesia and hepatic artery pump placement.
- Patients with chronic hepatitis and/or cirrhosis are eligible
- Serum albumin must be >2.5 g/dl and total serum bilirubin must be <1.8 mg/dl based on preoperative laboratory values within 14 days of registration.
- WBC must be >3500 cells/mm3 and platelet count must be >100,000/mm3 based on preoperative laboratory values within 14 days of registration.
- The international normalized ratio (INR) must be less than 1.5 in patients not on coumadin therapy, based on preoperative laboratory values within 14 days of registration.
- Age >_ 18 years.
- Female patients cannot be pregnant or lactating.
- Patients must be able to understand and sign informed consent.
Exclusion Criteria:
- Patients who have received prior treatment with FUDR
- Patients who have had prior external beam radiation therapy to the liver.
- Patients who have a diagnosis of sclerosing cholangitis.
- Patients who have a diagnosis of Gilbert's disease.
- Patients who have clinical ascites
- Patients with hepatic encephalopathy
- Patients who have radiographic evidence of esophageal varices or history of variceal hemorrhage.
- Patients with occlusion of the main portal vein nor of the right and left portal branches Patients that have concurrent malignancies (except localized basal cell or squamous cell skin cancers). Patient with active infection. Female patients who are pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
[0.16* mg/kg/day X 30 ml] / pump flow rate * If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Response
Time Frame: Up to 5 years
|
To assess the efficacy of continuous arterial infusion (HAI) of FUDR (Floxuridine) and dexamethasone (DEX) in patients with unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
|
Up to 5 years
|
Number of Patients With Treatment Related Toxicity
Time Frame: Up to 5 years
|
Toxicity evaluated and graded according to the National Cancer Institute, CTCAE v4.0
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Progression
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Median Survival
Time Frame: Up to 5 years
|
Median Survival from Initiation of Hepatic Arterial Infusion
|
Up to 5 years
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-120
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Cancer
-
National Institutes of Health Clinical Center (CC)CompletedLiver Cancer | Hepatic Cancer | Neoplasms, Liver | Hepatic NeoplasmsUnited States
-
AdventHealthCompletedHepatic Cancer | Hepatic Carcinoma | Hepatic NeoplasmUnited States
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAscending Colon Cancer | Ileocaecal Valve Carcinoma | Cancer Flexure Hepatic | Adenocarcinoma of Hepatic Flexure (Diagnosis)China
-
Midwestern Regional Medical CenterTerminatedCancer | Hepatic InjuryUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
AstraZenecaCompletedHepatic Impairment | Advanced CancerNetherlands, Denmark
-
National Cancer Institute (NCI)CompletedColorectal Cancer With Hepatic Metastases | Pancreas Cancer With Hepatic Metastase | Gastric Cancer With Hepatic Metastase | Breast Cancer With Hepatic Metastase | Ovarian Cancer With Hepatic MetastaseUnited States
-
Daiichi Sankyo, Inc.Medpace, Inc.CompletedCancer | Solid Tumor | Hepatic ImpairmentUnited States
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionBelgium, Germany, Israel, Bulgaria, United States
Clinical Trials on FLOXURIDINE
-
IRCCS San RaffaeleUnknown
-
NYU Langone HealthNational Cancer Institute (NCI)CompletedGastric Cancer | Colorectal Cancer | Small Intestine Cancer | Ovarian Cancer | Peritoneal Cavity Cancer | Gastrointestinal Stromal Tumor | Gastrointestinal Carcinoid TumorUnited States
-
NYU Langone HealthFood and Drug Administration (FDA)CompletedStomach Cancer | Gastric CancerUnited States
-
NSABP Foundation IncNational Cancer Institute (NCI)TerminatedColorectal Cancer | Metastatic CancerUnited States
-
Spectrum Health HospitalsRecruitingPancreatic Adenocarcinoma | Liver MetastasesUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedColorectal Cancer | Metastatic CancerUnited States
-
Luye Pharma Group Ltd.Enrolling by invitation
-
NYU Langone HealthNational Cancer Institute (NCI)CompletedGastric CancerUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Rutgers, The State University of New Jersey; University of Medicine and...Completed
-
University of ZurichCompletedCholangiocellular CarcinomaSwitzerland